A Phase 2 interventional study of Bleomycin and Brentuximab Vedotin in Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma and Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, sponsored by City of Hope Medical Center. Active, not recruiting at 17 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment
How we know · 13 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 12th largest by enrollment, is one of 5 that started in 2018, is one of 41 in phase 2, reaches primary completion later than 8 of the 27 other live ones, and was the 60th registered.
1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
38 studies in Hodgkin Disease by City of Hope Medical Center: 5 open now, 15 under way, none of them phase 3. Of 21 finished, 6 (29%) have results posted.
Among the 38 studies in Hodgkin Disease by City of Hope Medical Center, this one is the 4th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2018, is one of 18 in phase 2, reaches primary completion later than 7 of the 14 other live ones, and was the 26th registered.
City of Hope Medical Center’s Hodgkin Disease studies by the year they started, since 1998.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among City of Hope Medical Center’s 38 in Hodgkin Disease:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
PRIMARY OBJECTIVE:
I. Determine the 18-month progression free survival (PFS) for each arm of therapy stratified by positron emission tomography (PET)/computed tomography (CT)-2 response.
SECONDARY OBJECTIVES:
I. Assess safety, tolerability, and quality of life (QOL) for each arm of therapy.
II. Measure PET/CT-2 negativity rate after 2 lead-in cycles of standard of care doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD).
III. Evaluate the 3-year PFS and overall survival (OS) for each arm of treatment.
EXPLORATORY OBJECTIVES:
I. Evaluate if a baseline antitumor immune response, as assessed by a Nanostring gene panel, correlates with PFS.
II. Evaluate if minimal residual disease (MRD) status, as monitored by cancer personalized profiling by deep sequencing (CAPP-Seq) of circulating tumor (ct) deoxyribonucleic acid (DNA), can be correlated with PFS.
OUTLINE: Patients are assigned to 1 of 2 groups based on their PET/CT-2 scans.
GROUP I (PET/CT-2 NEGATIVE): Patients without bulky disease are randomized to either Arm A or B and patients with bulky disease are assigned to Arm B.
ARM A: Patients receive brentuximab vedotin intravenously (IV) over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
GROUP II (PET/CT-2 POSITIVE): Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented of the participant and/or legally authorized representative.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Brentuximab Vedotin · Biological: Nivolumab · Other: Quality-of-Life Assessment
Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Bleomycin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine
Patients with bulky diseases at diagnosis receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Bleomycin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine
Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Other: Quality-of-Life Assessment · Drug: Vinblastine
Given IV
Also known as: BLEO, BLM
Given IV
Also known as: ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35
Given IV
Also known as: 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007
Given IV
Also known as: Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin
Given IV
Also known as: BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Ancillary studies
Also known as: Quality of Life Assessment
Given IV
Also known as: Vincaleucoblastine, VLB
18-month Progression-free Survival (PFS) for Each Arm of Therapy
Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.
Time frame: Up to 18 months
Number of Patients Experiencing Grade 3-5 Adverse Events Related to Study Treatment
Toxicities were recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The events are possible, probable, or definite attribution to the study treatment.
Time frame: Up to 4 years
2-year Progression-free Survival (PFS) for Each Arm of Therapy
Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.
Time frame: Up to 2 years
| Milestone | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) |
|---|---|---|---|---|
| Started | 45 | 36 | 35 | 37 |
| Completed | 38 | 28 | 30 | 29 |
| Not completed | 7 | 8 | 5 | 8 |
| Withdrew: Adverse event | 4 | 4 | 3 | 1 |
| Withdrew: Physician decision | 1 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 2 |
| Withdrew: Progression | 0 | 0 | 0 | 2 |
| Withdrew: Due to partial response | 0 | 0 | 0 | 2 |
| Withdrew: Participant wished to pursue radiation therapy instead | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.
| percentage of participants | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) |
|---|---|---|---|---|
| 18-month Progression-free Survival (PFS) for Each Arm of Therapy | 100 (NA to NA) | 100 (NA to NA) | 97 (81 to 100) | 85 (68 to 94) |
Toxicities were recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The events are possible, probable, or definite attribution to the study treatment.
| Participants | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) |
|---|---|---|---|---|
| Number of Patients Experiencing Grade 3-5 Adverse Events Related to Study Treatment | 0 | 15 | 13 | 1 |
Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.
| percentage of participants | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) |
|---|---|---|---|---|
| 2-year Progression-free Survival (PFS) for Each Arm of Therapy | 100 (NA to NA) | 100 (NA to NA) | 86 (67 to 95) | 77 (57 to 89) |
Collected over From initiation of treatment through the end of protocol, up to 4 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Brentuximab Vedotin, Nivolumab) | 0/45 (0%) | 7/45 (15.6%) | 41/45 (91.1%) |
| Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | 0/36 (0%) | 5/36 (13.9%) | 36/36 (100%) |
| Arm B2 (ABVD, Nivolumab) for Bulky Patients | 0/35 (0%) | 4/35 (11.4%) | 35/35 (100%) |
| Arm C (AVD, Brentuximab Vedotin, Nivolumab) | 0/37 (0%) | 9/37 (24.3%) | 37/37 (100%) |
| Event | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) |
|---|---|---|---|---|
| FEVERGeneral disorders | 1/45 | 1/36 | 0/35 | 4/37 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/45 | 1/36 | 3/35 | 3/37 |
| COVID-19Infections and infestations | 0/45 | 0/36 | 0/35 | 2/37 |
| RASH MACULO-PAPULARSkin and subcutaneous tissue disorders | 2/45 | 0/36 | 0/35 | 0/37 |
| NON-CARDIAC CHEST PAINGeneral disorders | 0/45 | 0/36 | 1/35 | 0/37 |
| DEVICE RELATED INFECTIONInfections and infestations | 0/45 | 0/36 | 1/35 | 0/37 |
| DIARRHEAGastrointestinal disorders | 0/45 | 1/36 | 0/35 | 0/37 |
| INFLUENZAInfections and infestations | 0/45 | 1/36 | 0/35 | 0/37 |
| INFLUENZA AInfections and infestations | 0/45 | 1/36 | 0/35 | 0/37 |
| VASCULAR ACCESS COMPLICATIONInjury, poisoning and procedural complications | 0/45 | 1/36 | 0/35 | 0/37 |
| Event | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) |
|---|---|---|---|---|
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 9/45 | 8/36 | 6/35 | 27/37 |
| CONSTIPATIONGastrointestinal disorders | 4/45 | 11/36 | 9/35 | 23/37 |
| FATIGUEGeneral disorders | 9/45 | 19/36 | 9/35 | 20/37 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 3/45 | 18/36 | 18/35 | 17/37 |
| NAUSEAGastrointestinal disorders | 11/45 | 16/36 | 12/35 | 19/37 |
| BONE PAINMusculoskeletal and connective tissue disorders | 1/45 | 1/36 | 1/35 | 19/37 |
| ANEMIABlood and lymphatic system disorders | 3/45 | 9/36 | 6/35 | 14/37 |
| VOMITINGGastrointestinal disorders | 5/45 | 9/36 | 7/35 | 14/37 |
| RASH MACULO-PAPULARSkin and subcutaneous tissue disorders | 17/45 | 4/36 | 6/35 | 6/37 |
| DYSPNEARespiratory, thoracic and mediastinal disorders | 6/45 | 12/36 | 10/35 | 8/37 |
| Age, Continuous(years) | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) | Total |
|---|---|---|---|---|---|
| Median | 30 (18 to 69) | 33 (19 to 73) | 28 (18 to 64) | 32 (18 to 63) | 31 (18 to 73) |
| Sex: Female, Male(Participants) | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) | Total |
|---|---|---|---|---|---|
| Female | 22 | 18 | 17 | 18 | 75 |
| Male | 23 | 18 | 18 | 19 | 78 |
| Ethnicity (NIH/OMB)(Participants) | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 5 | 1 | 20 |
| Not Hispanic or Latino | 35 | 29 | 27 | 35 | 126 |
| Unknown or Not Reported | 2 | 1 | 3 | 1 | 7 |
| Race (NIH/OMB)(Participants) | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 | 2 |
| Black or African American | 3 | 1 | 2 | 2 | 8 |
| White | 33 | 32 | 23 | 29 | 117 |
| More than one race | 1 | 1 | 0 | 0 | 2 |
| Unknown or Not Reported | 7 | 0 | 6 | 1 | 14 |
| Region of Enrollment(participants) | Arm A (Brentuximab Vedotin, Nivolumab) | Arm B1 (ABVD, Nivolumab) for Non-bulky Patients | Arm B2 (ABVD, Nivolumab) for Bulky Patients | Arm C (AVD, Brentuximab Vedotin, Nivolumab) | Total |
|---|---|---|---|---|---|
| United States | 45 | 36 | 35 | 37 | 153 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Nov 2024, 72 months.
Results were first posted in Oct 2026, 1 year 10 months after primary completion.
Of 180 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's 72 months is close to that.
Counting every sponsor, half of 203 studies reached it within 75 months; a quarter within 42 and three quarters within 111.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2024 → Nov 2024 and completion Dec 2024 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Dacarbazine · Doxorubicin · Nivolumab · Vinblastine